Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Drug Manufacturers - Specialty & Generic

Healthcare
$28.96 +1.17%

+$0.51 today

Market cap
$6.02B
Beta
0.54
P/E (TTM)
-87.6
EPS (TTM)
-$0.50
52W Low $30.83High $59.68

Volume 2.71M

Average 0.64M

SUPN Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Supernus Pharmaceuticals, Inc.NASDAQ: SUPN

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables turns negative

Q2 FY2026 accounts receivables was -$29.47M, compared with $4.81M a year earlier. Trailing-twelve-month accounts receivables was -$47.41M. Over 3 fiscal years it compounded at +10.9% a year.

Context

  • Accounts receivables amounted to 3.1% of revenue in FY2025, up 2.8 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$29.47M or moves back toward the trailing-twelve-month quarterly average of -$11.85M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$29.47M-624.5% QoQ
Last fiscal yearDec 2025
-$22.3M-1173.3% YoY
LTMJun 2026
-$47.41M-506.5% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-712.9%——
1 year-1173.3%——
3-year CAGR+10.9%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(22.3M) USD
Year-over-year change
-1173.3%

Accounts Receivables vs competitors

How SUPN compares with its peers on the latest reported figures

  • SUPN's LTM Jun 2026 accounts receivables of $47.41M is the 2nd largest of the 3 companies compared; the peer median is $29.63M.
  • Its year-over-year change of -506.5% is the lowest of 3, against a peer median of +538.2%.
  • Accounts receivables amounts to 5.7% of revenue for SUPN, versus a peer median of 1.7%.
SUPN Competitors Peer median
Accounts Receivables for SUPN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALKSAlkermes plcLTM Sep 2026$59.21M +1175.7%+30.0%3.4%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$47.41M -506.5%+10.9%5.7%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$60K -99.4%—0.0%
Peer median (excluding SUPN) $29.63M+538.2%+30.0%1.7%

Competitors are the stored peer set for SUPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income53.42M60.71M1.32M73.87M(38.55M)
Depreciation & Amortization32.6M85.54M84.86M80.41M91.56M
Deferred Income Tax(4.99M)(26.32M)(25.71M)(20.14M)5.21M
Stock-Based Compensation17.91M17.57M26.76M27.76M33.05M
Change in Working Capital3.57M(24.24M)(9.14M)(2.05M)(75.16M)
Accounts Receivables3.87M(16.37M)18.77M2.08M(22.3M)
Inventory(14.58M)(17.86M)6.11M15.81M(7.5M)
Accounts Payables18.18M(19.16M)(36.29M)(15.02M)(24.57M)
Other Working Capital(3.9M)29.14M2.28M(4.92M)(20.79M)
Other Non-Cash Items24.62M3.57M33M12.11M31.22M
Operating Cash Flow127.13M116.83M111.09M171.95M47.33M
Capital Expenditures(2.05M)(412K)(551K)(725K)(1.34M)
Acquisitions (Net)(311.69M)(14K)00(293.09M)
Purchases of Investments(311.57M)(406.99M)(101.62M)(688.01M)(475.94M)
Sales of Investments530.51M190.74M370.9M498.86M774.92M
Other Investing Activities12.89M14K09K(439K)
Investing Cash Flow(81.91M)(216.66M)268.73M(189.87M)4.11M
Debt Repayment(137.52M)0(402.5M)00
Common Stock Issued7.1M12.42M6.61M14.91M37.62M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(22.9M)(1.99M)(2.72M)(28.49M)
Financing Cash Flow(130.42M)(10.48M)(397.88M)12.19M9.13M
Effect of Forex Changes00000
Net Change in Cash(85.21M)(110.31M)(18.07M)(5.72M)60.57M
Free Cash Flow125.08M116.41M110.53M171.23M45.99M

Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Intrinsic Alpha fair value

Locked

Current Price

$28.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.